<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215500</url>
  </required_header>
  <id_info>
    <org_study_id>13619B</org_study_id>
    <nct_id>NCT01215500</nct_id>
  </id_info>
  <brief_title>Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer</brief_title>
  <official_title>A Study of Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with metastatic cancer are generally treated with chemotherapy, which has improved&#xD;
      median survival compared to best supportive care. Despite this, patients continue to have&#xD;
      persistent disease at sites that were initially involved with cancer. Radiation therapy is an&#xD;
      effective modality for treating localized cancer but generally has been only used for&#xD;
      palliation of symptoms once a patient develops metastatic disease. Since patients often have&#xD;
      persistent disease after chemotherapy, the goal of this trial is to use increasing doses of&#xD;
      radiation therapy to all sites of involved disease in order to determine the safety and&#xD;
      efficacy of hypofractionated radiation therapy.&#xD;
&#xD;
      The purpose of this study is to establish a maximum tolerated dose, dose-limiting toxicities,&#xD;
      and recommended phase 2 dose of hypofractionated radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>30-90 days</time_frame>
    <description>The dose limiting toxicities occurring within the initial observation period will be defined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum tolerated dose of hypofractionated RT</measure>
    <time_frame>30-90 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Tumor</condition>
  <condition>Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Sarcoma</condition>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated RT</intervention_name>
    <description>RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:&#xD;
For all sites the dose levels are as follows:&#xD;
8 Gy/ fraction x 3 fractions = 24 Gy&#xD;
10 Gy/fraction x 3 fractions = 30 Gy&#xD;
12 Gy/fraction x 3 fractions = 36 Gy&#xD;
14 Gy/fraction x 3 fractions = 42 Gy&#xD;
16 Gy/fraction x 3 fractions = 48 Gy&#xD;
18 Gy/fraction x 3 fractions = 52 Gy&#xD;
20 Gy/fraction x 3 fractions = 60 Gy</description>
    <arm_group_label>Radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of cancer (including epithelial&#xD;
             carcinoma, sarcoma, and melanoma)&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Life expectancy of &gt; 3 months&#xD;
&#xD;
          -  Patients with AJCC (6th edition, 2002) stage IV cancer with distant metastases and&#xD;
             without pleural or pericardial effusion at diagnosis and before start of study&#xD;
&#xD;
          -  Patients with 1-5 sites of maximum tumor dimension (for each individual site) of ≤ 10&#xD;
             cm or &lt; 500 cc volume and amenable to radiation therapy as seen on standard imaging&#xD;
&#xD;
          -  Unidimensionally measurable disease (based on RECIST) is desirable but not strictly&#xD;
             required&#xD;
&#xD;
          -  Brain metastases must have been treated prior to enrollment on study, preferably with&#xD;
             stereotactic radiosurgery&#xD;
&#xD;
          -  ECOG performance status ≤ 2 or Karnofsky Performance Status ≥ 60%&#xD;
&#xD;
          -  No prior radiation therapy to currently involved tumor sites&#xD;
&#xD;
          -  Room air saturation &gt; 90%&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dl&#xD;
&#xD;
          -  ANC &gt;=1,500/microliter&#xD;
&#xD;
          -  Platelets &gt;=100,000/microliter&#xD;
&#xD;
          -  Total bilirubin within institutional limits&#xD;
&#xD;
          -  Albumin &gt; 2.9 g/dl&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5x upper limit of normal&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 x upper limit of normal&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any&#xD;
             history of clinically significant CHF are excluded. Exclusion of patients with active&#xD;
             coronary heart disease will be at the discretion of the attending physician&#xD;
&#xD;
          -  Patients with significant atelectasis such that CT definition of gross tumor volume is&#xD;
             difficult to determine&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Patients must have no uncontrolled active infection other than that not curable with&#xD;
             treatment of their cancer.&#xD;
&#xD;
          -  Patients may not be receiving any other investigational drugs during RT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Chmura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor cancer</keyword>
  <keyword>epithelial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

